Larvol Delta - Longitudinal-laboratory-profile-of-patients-with-moderatetosevere-atopic-dermatitis-treated-with-lebrikizumab-or-tralokinumab-in-realworld-clinical-practice

Ebglyss (lebrikizumab-lbkz) - Eli Lilly

Adbry (tralokinumab-ldrm) - LEO Pharma, AstraZeneca

https://pagv3.virtual-meeting.org/eadv/eadvcongress2026/en-GB/pag/presentation/62276

Carolina Montero-Vilchez

Aug 6, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next